WESTBROOK, Maine, April 2, 2008 /PRNewswire-FirstCall/ -- IDEXX Laboratories, Inc. (Nasdaq: IDXX) today announced that it has shipped, delivered and recognized first quarter revenue for initial customer deliveries and installations of its two next-generation point-of-care analyzers: the Catalyst Dx(TM) for chemistry analysis and the SNAPshot Dx(TM) for endocrinology testing. Catalyst Dx combines the convenience of immediate results with the accuracy, flexibility, and menu breadth of a reference laboratory, and SNAPShot Dx provides the ability to quickly and conveniently screen for hypothyroidism, hyperthyroidism, Cushing's syndrome, Addison's disease, liver disease and other conditions at the point of care.
Both Catalyst Dx and SNAPshot Dx offer veterinarians enhancements in ease-of-use, speed-to-result, accuracy and throughput, with the ability to run multiple samples for more than one patient simultaneously. In addition, each instrument captures all results in the electronic medical record and automatically integrates the data into the patient diagnostic report and invoice, improving overall practice productivity and workflow efficiencies.
"I am very pleased that we are delivering these important new products on the schedule we outlined over a year ago," said Jonathan W. Ayers, Chairman and Chief Executive Officer. "We have successfully met the key milestones for this complex project, concurrently completing the development, field test and validation for two major diagnostic instrument systems."
The addition of these two innovative instruments to the IDEXX VetLab(R)
Suite of in-house analyzers continues the IDEXX tradition of delivering new
technologies to the veterinary market that expand the range of
|SOURCE IDEXX Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved